Prescription Medicine

Major Cancers


Eloxatin (oxaliplatin)

Eloxatin® (oxaliplatin) is a platinum salt which works by forming a chemical bond with DNA and disrupting the process of fast growing cell division. It is indicated for Stage III adjuvant colon cancer and Stage IV metastatic colorectal cancer.

Registered and launched in Hong Kong in 2000, Eloxatin is also marketed in around 70 countries throughout the world. In 2008, a new aqueous formulation of Eloxatin was launched to facilitate the preparation of chemotherapy treatment by nursing staff or pharmacists. 

Reference: Eloxatin Hong Kong Prescribing Information.

Jevtana (cabazitaxel)

Jevtana® (Cabazitaxel) is a microtubule inhibitor, indicated to be used in combination with prednisone or prednisolone for the treatment of adult patients with hormone refractory metastatic prostate cancer.

Jevtana’s formulation is Concentrate and solvent solution for dilution. Jevtana is administered as a 1-hour intravenous infusion every 3 weeks in combination with oral prednisone or prednisolone 10mg administered daily throughout the treatment.

Reference: Jevtana Hong Kong Prescribing Information.

Thyrogen (thyrotropin alfa)

Thyrogen® is indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Thyrogen is also indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Reference: Thyrogen Hong Kong Prescribing Information.

Zaltrap (aflibercept)

ZALTRAP® in combination with irinotecan/5 fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin containing regimen.

The recommended dose of Zaltrap, administered as an intravenous infusion over 1 hour, is 4 mg/kg of body weight, followed by the FOLFIRI regimen. This is considered as one treatment cycle. The treatment cycle is repeated every 2 weeks.

Reference: Zaltrap Hong Kong Prescribing Information.